Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  1994-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF01533517PMID 8168121PMCID PMC11038170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Clinical Trials with VMO for Melanoma

  1993cited by this paper
• Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.

  1992cited by this paper
• Clonal expansion of T cells following in vitro stimulation with autologous melanoma cells and interleukin-2 studied by molecular analysis of a T cell receptor.

  1991cited by this paper
• Recent advances in cellular immunology: implications for immunity to cancer.

  1990cited by this paper
• Pharmacokinetics of recombinant interleukin 2 in humans.

  1990cited by this paper
• Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2.

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

  1990cited by this paper
• T‐Cell Clones that react against Autologous Human Tumors

  1990cited by this paper
• Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model

  1990influential reference
• Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

  1989cited by this paper
• Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies.

  1989cited by this paper
• Murine interleukin-4 displays potent anti-tumor activity in vivo.

  1989cited by this paper
• Functionally different HTLV I-infected T cell lines with the same phenotype derived from a patient with melanoma.

  1989cited by this paper
• Interferons: biological and clinical effects.

  1989cited by this paper
• Vaccinia virus‐infected C‐C36 colon tumor cell lysates stimulate cellular responses in vitro and protect syngeneic balb/c mice from tumor cell challenge

  1989cited by this paper
• Identification of a human homologue of the murine tumor rejection antigen GP96.

  1989cited by this paper
• Presence on a human melanoma of multiple antigens recognized by autologous CTL

  1989cited by this paper
• Lymphotoxin.

  1988cited by this paper
• Effects of interferon-gamma on the activation of human T lymphocytes.

  1988cited by this paper
• Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

  1988cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy.

  1988cited by this paper
• Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

  1988cited by this paper
• Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.

  1988cited by this paper
• Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

  1988cited by this paper
• Effects of interferon-? on the activation of human T lymphocytes

  1988cited by this paper
• Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

  1987cited by this paper
• Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

  1987cited by this paper
• Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression

  1987cited by this paper
• Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma

  1987cited by this paper
• Clonal analysis of the cytolytic T-cell response to human tumors.

  1987cited by this paper
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.

  1987cited by this paper
• Phase I study of recombinant tumor necrosis factor in cancer patients.

  1987cited by this paper
• A novel approach to the generation and identification of experimental hepatic metastases in a murine model.

  1986cited by this paper
• A southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates

  1986cited by this paper
• Interferons and interferon inducers in cancer treatment.

  1986cited by this paper
• Interferons and interferon inducers in cancer treatment.

  1986cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Interferon therapy in cancer: from imaginon to interferon.

  1986cited by this paper
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

  1986cited by this paper
• Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates.

  1984cited by this paper
• A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate

  1983cited by this paper
• Specific tumor immunity produced by the injection of vaccinia viral oncolysates.

  1982cited by this paper
• Specific immunotherapy with vaccinia oncolysates

  1981cited by this paper
• A new approach in specific, active immunotherapy

  1977cited by this paper
• VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUS

  1967cited by this paper
• A comparative morphological study of the mammary gland in a high and a low tumor strain of mice.

  1938cited by this paper

• Carbon Nanotubes in Biomedical Applications

  2014cites this paper
• Oncolytic vaccinia virus for the treatment of cancer

  2011cites this paper
• Oncolytic vaccinia virus: a theranostic agent for cancer

  2010cites this paper
• Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy.

  2008cites this paper
• Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

  2007cites this paper
• A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.

  2007cites this paper
• Expression of melanoma-associated antigens in human dendritic cells pulsed with an interleukin-2 gene encoded vaccinia melanoma oncolysate (rIL-2VMO)

  2006cites this paper
• Promises and Limitations of Murine Models in the Development of Anticancer T-Cell Vaccines

  2006cites this paper
• The treatment of melanoma with an emphasis on immunotherapeutic strategies.

  2006cites this paper
• Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus

  2005cites this paper
• Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer

  2002cites this paper
• Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.

  2000cites this paper
• Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.

  1999cites this paper
• Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

  1998cites this paper
• Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice

  1998cites this paper
• Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.

  1997cites this paper
• Gene therapy strategies for carcinoma of the breast

  1997cites this paper
• Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model.

  1997cites this paper
• Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.

  1996cites this paper
• Immunotherapy in liver tumors: III. A new experimental model of metastatic liver tumors from colorectal carcinoma for cytokine therapy.

  1995cites this paper
• Cytokine gene-modified vaccines for immunotherapy of cancer (review).

  1995cites this paper
• Immunotherapy in liver tumours: I. Combined administration of recombinant interleukin-2 (IL-2) and interferon-alpha through the subcutaneous transposed spleen prolongs the half-life of IL-2 in vivo and enhances antitumor effects.

  1994cites this paper
• Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.

  1994cites this paper